Company Description
KalVista Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs.
The company’s product candidate is EKTERLY, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).
It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks.
KalVista Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 270 |
| CEO | Benjamin Palleiko |
Contact Details
Address: 55 Cambridge Parkway, Suite 901 East Cambridge, Massachusetts 02142 United States | |
| Phone | 857 999 0075 |
| Website | kalvista.com |
Stock Details
| Ticker Symbol | KALV |
| Exchange | NASDAQ |
| Fiscal Year | May - April |
| Reporting Currency | USD |
| CIK Code | 0001348911 |
| CUSIP Number | 483497103 |
| ISIN Number | US4834971032 |
| Employer ID | 20-0915291 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Benjamin L. Palleiko | Chief Executive Officer and Director |
| Brian Piekos | Chief Financial Officer |
| Dr. Paul K. Audhya M.B.A., M.D. | Chief Medical Officer |
| Bilal Arif | Chief Operating Officer |
| Ryan Baker | Head of Investor Relations |
| Brian Krex J.D. | General Counsel |
| Jarrod Aldom | Vice President of Corporate Communications |
| Linea Aspesi | Chief People Officer |
| Rachel M. Morten | Senior Vice President of Regulatory Affairs and QA |
| Dr. Christopher M. Yea Ph.D. | Chief Development Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2025 | SCHEDULE 13G/A | Filing |
| Nov 10, 2025 | 10-Q | Quarterly Report |
| Nov 10, 2025 | 8-K | Current Report |
| Nov 10, 2025 | SCHEDULE 13G | Filing |
| Nov 4, 2025 | SCHEDULE 13D/A | Filing |
| Oct 6, 2025 | 8-K | Current Report |
| Oct 2, 2025 | 8-K | Current Report |
| Sep 29, 2025 | 8-K | Current Report |
| Sep 11, 2025 | 10-Q | Quarterly Report |
| Sep 11, 2025 | 8-K | Current Report |